Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

1. Vascular permeability in the fibrotic lung.The European respiratory journal · 2020
   Article
2. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy.Core evidence · 2016
   Review
3. Update on therapeutic management of idiopathic pulmonary fibrosis.Therapeutics and clinical risk management · 2015
   Review
4. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future.European respiratory review : an official journal of the European Respiratory Society · 2013
   Review

Corrections and comments

• Commented on by
  Warfarin in idiopathic pulmonary fibrosis: friend or foe, is it a matter of genes and heparin? : a reply to Tzouvelekis.2013
• Comment on
  A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.2012

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as